Skip to main content

Richard Ronald's Form 4 filing

Emergent BioSolutions Inc. (EBS) · filed Dec 9, 2025

Accession no.
0001380177-25-000006
Filed
Dec 9, 2025
Trade date
Dec 5, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $263.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Richard RonaldCIK 0001380177Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 5, 2025Common StockSSaleDisposed−7,100$12.11F2−$85,98198,417Direct
Dec 5, 2025Common StockMOption exerciseAcquired+25,748$5.02+$129,254.96124,165Direct
Dec 5, 2025Common StockFTax withholdingDisposed−10,864$11.90F4−$129,281.6113,301Direct
Dec 5, 2025Common StockSSaleDisposed−14,884$11.90F4−$177,119.698,417Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 5, 2025Common StockMOption exerciseDisposed−25,748$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.11 to $12.12.

Referenced by the price of 1 transaction in Table I.

F4

The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $11.88 to $11.97.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)